Prochlorperazine
Compro, Prochlorperazine, Procomp (prochlorperazine) is a small molecule pharmaceutical. Prochlorperazine was first approved as Compazine on 1982-01-01. It is used to treat anxiety disorders, dementia, nausea, psychotic disorders, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(3) dopamine receptor and D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor and D(4) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Compro, Prochlorperazine, Procomp (discontinued: Compazine, Prochlorperazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prochlorperazine maleate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| compro | ANDA | 2025-03-20 |
| prochlorperazine | ANDA | 2023-11-29 |
| prochlorperazine edisylate | ANDA | 2025-06-23 |
| prochlorperazine maleate | ANDA | 2025-10-02 |
| prochlorperazine maleate prochlorperazine maleate | ANDA | 2025-07-11 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0780 | Injection, prochlorperazine, up to 10 mg |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
| S0183 | Prochlorperazine maleate, oral, 5 mg (for circumstances falling under the medicare statute, use q0164) |
Clinical
Clinical Trials
49 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 2 | 5 | 4 | 6 | 4 | 20 |
| Headache | D006261 | — | R51 | 1 | 4 | 2 | 6 | 1 | 13 |
| Vomiting | D014839 | — | R11.1 | — | 2 | 4 | 1 | — | 7 |
| Nausea | D009325 | — | R11.0 | — | 2 | 2 | 1 | — | 5 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | 1 | — | 1 | — | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 3 | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | 1 | — | — | 2 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | — | — | 1 |
| Inflammatory breast neoplasms | D058922 | — | — | — | — | 1 | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | — | — | 1 | — | — | 1 |
| Facial neuralgia | D005156 | EFO_0009380 | 351.8 | — | — | 1 | — | — | 1 |
| Vertigo | D014717 | — | H81.39 | — | — | 1 | — | — | 1 |
| Dizziness | D004244 | — | R42 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | 1 | 3 |
| Emergencies | D004630 | — | — | 1 | 2 | — | — | 1 | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | — | — | 1 | 2 |
| Primary headache disorders | D051270 | — | G44.53 | — | 1 | — | — | 1 | 2 |
| Alveolar soft part sarcoma | D018234 | — | — | — | 1 | — | — | — | 1 |
| Pain management | D059408 | — | — | — | 1 | — | — | — | 1 |
| Agnosia | D000377 | EFO_0007136 | F88 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 1 | — | — | — | 1 |
| Peritoneal neoplasms | D010534 | — | — | 1 | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 1 | 1 |
| Headache disorders | D020773 | EFO_0009550 | G44 | — | — | — | — | 1 | 1 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | — | — | 1 | 1 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | — | — | 1 | 1 |
| Tension-type headache | D018781 | — | G44.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prochlorperazine |
| INN | prochlorperazine |
| Description | Prochlorperazine is a member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. It has a role as an antiemetic, a dopaminergic antagonist, an alpha-adrenergic antagonist, a cholinergic antagonist, a first generation antipsychotic, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and a dopamine receptor D2 antagonist. It is an organochlorine compound, a N-alkylpiperazine, a N-methylpiperazine and a member of phenothiazines. It derives from a hydride of a 10H-phenothiazine. |
| Classification | Small molecule |
| Drug class | Typical antipsychotic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 58-38-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL728 |
| ChEBI ID | 8435 |
| PubChem CID | 4917 |
| DrugBank | DB00433 |
| UNII ID | YHP6YLT61T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
S100A4
S100A4
Organism
Homo sapiens
Gene name
S100A4
Gene synonyms
CAPL, MTS1
NCBI Gene ID
Protein name
protein S100-A4
Protein synonyms
calcium placental protein, Calvasculin, fibroblast-specific protein-1, leukemia multidrug resistance associated protein, malignant transformation suppression 1, Metastasin, metastasin 1, murine placental homolog, Placental calcium-binding protein, Protein Mts1, S100 calcium-binding protein A4, S100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog)
Uniprot ID
Mouse ortholog
S100a4 (20198)
protein S100-A4 (P20066)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Prochlorperazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,262 documents
View more details
Safety
Black-box Warning
Black-box warning for: Compro, Prochlorperazine, Prochlorperazine edisylate, Prochlorperazine maleate, Prochlorperazine maleate prochlorperazine maleate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,597 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use